Mild Haemostatic Problems Associated with Congenital Heterozygous α₂-Antiplasmin Deficiency

Summary

A Dutch family, of which 13 members are heterozygotes, deficient for α₂-antiplasmin (α₂-AP) is reported. Clinical studies showed that 2 heterozygotes had a mild bleeding tendency, which presented as bleeding episodes after tooth extraction and after surgery and, in one patient, also as excessive menstruation. Laboratory investigations revealed an α₂-AP activity of 62% (51-71) (median and range) and an antigen level of 60% (60-66). The plasminogen binding as well as the fibrin binding properties of α₂-AP were normal. Plasminogen concentrations were significantly higher in the heterozygotes compared to the other family members. However, free plasminogen not bound to histidine-rich glycoprotein was not significantly different between these two groups. We propose that in this family the deficiency of α₂-AP is due to a decreased synthesis of a normal α₂-AP molecule. This present study brings the frequency of heterozygous α₂-AP deficient patients with a bleeding tendency to 13 out of 59 heterozygotes reported in the literature.

Key words

Fibrinolysis - α₂-antiplasmin - Deficiency - Plasminogen - Haemorrhagic diathesis

• References

• 1 Collen D. Identification and some properties of a new fast reacting plasma inhibitor in human plasma. Eur J Biochem 1976; 69: 209-216
• 2 Moroi M, Aoki N. Isolation and characterization of α₂-plasmin inhibitor from human plasma. J Biol Chem 1976; 251: 5956-5965
• 3 Saito H, Goodnough LT, Knowles BB, Aden DP. Synthesis and secretion of ob-plasmin inhibitor by established human liver cell lines. Proc Natl Acad Sci 1982; 79: 5684-5687
• 4 Hogstrop H, Saldeen T. Synthesis of α₂-antiplasmin by rat liver cells. Thromb Res 1982; 28: 19-25
• 5 Miillertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-553
• 6 Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26
• 7 Collen D, Wiman B. Fast-acting plasma inhibitor in human plasma. Blood 1978; 51: 563-569
• 8 Clemmensen I. Different molecular forms of α₂-antiplasmin. In: The physiological inhibitors of coagulation and fibrinolysis Collen D, Wiman B, Verstraete M. eds. Elsevier North Holland, Paramedical Press; Amsterdam: 1979: 131-136
• 9 Wiman B. Affinity-chromatographic purification of human α₂-antiplasmin. Biochem J 1980; 191: 229-232
• 10 Mimuro J, Kimura S, Aoki N. Release of α₂-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. It’s effect on fibrinolysis. J Clin Invest 1986; 77: 1006-1013
• 11 Moroi M, Aoki N. Inhibition of plasminogen binding to fibrin by α₂-plasmin inhibitor. Thromb Res 1977; 10: 851-856
• 12 Sakata Y, Aoki N. Cross-linking of α₂-plasmin inhibitor to fibrin stabilizing factor. J Clin Invest 1980; 65: 290-297
• 13 Kluft C, Los P. Demonstration of two forms of α₂-antiplasmin in plasma by modified crossed immunoelectrophoresis. Thromb Res 1981; 21: 65-71
• 14 Kluft C, Los P, Jie AF H, van Hinsbergh VW M, Vellenga EM, Jespersen JM, Henny Ch PM. The mutual relation of the two molecular forms of the major fibrinolysis inhibitor, α₂-antiplasmin in blood. Blood 1986; 67: 616-622
• 15 Clemmensen I, Thorsen S, Miillertz S, Petersen LC. Properties of three different molecular forms of the α₂-plasmin inhibitor. Eur J Biochem 1981; 120: 105-112
• 16 Kluft C, Los P, Jie AF H. The molecular form of α₂-antiplasmin with affinity for plasminogen is selectively bound to fibrin by factor XIII. Thromb Res 1984; 33: 419-425
• 17 Koie K, Kamiya T, Ogata K, Takamatsu J, Kobakura M. α₂-plasmin inhibitor deficiency (Miyasato disease). Lancet 1978; II: 1334-1336
• 18 Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of α₂-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979; 63: 877-884
• 19 Kluft C, Vellenga E, Rrommer EJ P. Homozygous α₂-antiplasmin deficiency. Lancet 1979; II: 206
• 20 Kluft C, Vellenga E, Brommer EJ P, Wijngaards G. A familial hemorrhagic diathesis in a Dutch family: An inherited deficiency of α₂-antiplasmin. Blood 1982; 59: 1169-1180
• 21 Miles LA, Plow EF, Donnelly KJ, Hougie C, Griffin JH. A bleeding disorder due to deficiency of α₂-antiplasmin. Blood 1982; 59: 1246-1257
• 22 Yoshioka A, Kamitsuji H, Takase T, Lida Y, Tsukada S, Mikami S, Fukui H. Congenital deficiency of α₂-plasmin inhibitor in three sisters. Haemostasis 1982; 11: 176-184
• 23 Stormorken H, Gogstad GO, Brosstad F. Hereditary α₂-antiplasmin deficiency. Thromb Res 1983; 31: 647-651
• 24 Kettle P, Mayne RR. A bleeding disorder due to a deficiency of α₂-antiplasmin. J Clin Pathol 1985; 38: 428-429
• 25 Kordich L, Feldman L, Porteie P, Lago O. Severe hemorrhagic tendency in heterozygous α₂-antiplasmin deficiency. Thromb Res 1985; 40: 645-651
• 26 Knot EA R, Ten Cate JW, Lamping RJ, Gie LiemKian. α₂-antiplasmin: Functional characterization and metabolism in a heterozygote deficient patient. Thromb Haemostas 1986; 55: 375-378
• 27 Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553
• 28 Friberger P, Knos M, Gustavsson S, Aurell L, Cleason G. Methods for the determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 7: 138-145
• 29 Laurell CB. Quantitative estimations of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 57-65
• 30 Kluft C, Preston FE, Malia RG, Bertina RM, Wijngaards G, Greaves M, Verheijen JH, Dooijewaard G. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemostas 1984; 51: 157-164
• 31 Koopman J, Haverkate F, Koppert P, Nieuwenhuizen W, Brommer EJ P, van der Werf WG C. A new enzyme immunoassay of fibrin(ogen) degradation products in plasma using a monoclonal antibody. In: Fibrinogen-Fibrin Formation and Fibrinolysis Vol.4 Lane DA, Henschen A, Jasani MK. eds. De Gruyter&Co; Berlin: 1986: 261-270
• 32 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-246
• 33 Recent Developments on Protein C. Boehringer Mannheim GmbH. Catno 4308 October 1983
• 34 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measuiement in plasma. Thromb Haemostas 1982; 48: 266-269
• 35 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast acting inhibitor of tissue type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
• 36 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in chemical fibrinolysis and thrombolysis Davidson JF, Samama MM, Desnoyers PC. eds. Vol.2 57-65 Raven Press; New York: 1976
• 37 Chohan IS, Vermylen J, Singh I, Balakrishnan K, Verstraete M. Sodium acetate buffer: A diluent of choice in the clot lysis time technique. Thrombos Diathes Haemorrh 1975; 33: 226-229
• 38 Nieuwenhuis HK, Kluft C, Wijngaards Gv, Berkel W, Sixma JJ. α₂-Antiplasmin Enschede: An autosomal recessive hemorrhagic disorder caused by a dysfunctional α₂-antiplasmin molecule. Thromb Haemostas 1983; 50: 170 (Abstr)
• 39 Kluft C, Nieuwenhuis HK, Rijken DC, Groeneveld E, Wijngaards Gv, Berkel W, Dooijewaard G, Sixma JJ. α₂-Antiplasmin Enschede: A dysfunctional α₂-antiplasmin molecule, associated with an autosomal recessive hemorrhagic disorder. J Clin Invest 1987 (in press)